CAR T Cells with a Dominant-Negative TGFβ Receptor Are Safe and Feasible

Area of Science:

• Oncology
• Immunotherapy
• Cellular Therapy

Background:

• Prostate cancer remains a significant health concern with limited treatment options for advanced stages.
• Prostate-specific membrane antigen (PSMA) is a promising target for cancer therapy due to its overexpression in prostate cancer cells.
• Transforming growth factor beta (TGF-β) signaling can suppress anti-tumor immune responses, hindering the effectiveness of cell-based therapies.

Purpose of the Study:

• To evaluate the safety and feasibility of PSMA-targeting chimeric antigen receptor (CAR) T cells engineered with a dominant-negative TGFβ receptor (dnTGFβR) in patients with prostate cancer.
• To assess the preliminary efficacy and immune response to this novel cellular therapy.

Main Methods:

• Phase I clinical trial involving patients with PSMA-positive metastatic castration-resistant prostate cancer.
• Administration of autologous T cells genetically modified to express a PSMA-targeting CAR and a dnTGFβR.
• Monitoring of safety, tolerability, and preliminary efficacy through clinical assessments and laboratory analyses.

Main Results:

• The PSMA-targeting CAR T cells with dnTGFβR were found to be safe and feasible in the studied patient cohort.
• No dose-limiting toxicities were observed, indicating a favorable safety profile.
• Preliminary signs of anti-tumor activity were noted, warranting further investigation.

Conclusions:

• PSMA-targeting CAR T cells incorporating a dnTGFβR represent a potentially safe and feasible therapeutic strategy for prostate cancer.
• The combination approach may overcome immune suppression mediated by TGF-β, enhancing CAR T cell function.
• Further clinical trials are needed to confirm efficacy and optimize treatment protocols.